bfb2d782-49b2-4452-b418-bc90cd007df1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 52.6680355920602
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.520
- INTERFERON_GAMMA_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.470
- COMPLEMENT+0.430
- INFLAMMATORY_RESPONSE+0.410
- ANGIOGENESIS+0.360
- HEDGEHOG_SIGNALING+0.360
- IL2_STAT5_SIGNALING+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
Top 10 suppressed
- P53_PATHWAY-0.220
- CHOLESTEROL_HOMEOSTASIS-0.210
- PANCREAS_BETA_CELLS-0.200
- OXIDATIVE_PHOSPHORYLATION-0.170
- PEROXISOME-0.160
- MYC_TARGETS_V2-0.140
- ADIPOGENESIS-0.130
- TGF_BETA_SIGNALING-0.120
- DNA_REPAIR-0.110
- MYC_TARGETS_V1-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R187 | — | — | 0.862 |
| 2 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.856 |
| 3 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.842 |
| 4 | R303 | — | — | 0.835 |
| 5 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.834 |
| 6 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.833 |
| 7 | TCGA-98-7454-01A-11R-2045-07 | — | cohortMD2 | 0.833 |
| 8 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.829 |
| 9 | BS_J1AB8PMA | Med | Medulloblastoma | 0.828 |
| 10 | MNG814 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.170 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |